• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[A case report of patient with advanced non-small cell lung cancer by five times EGFR-TKIs therapy].

作者信息

Guo Wanfeng, Gao Hongjun, Liu Xiaoqing

机构信息

Department of Lung Cancer, Affiliated Hospital, Academy of Military Medical Sciences, Beijing 100071, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2013 Jun;16(6):330-2. doi: 10.3779/j.issn.1009-3419.2013.06.11.

DOI:10.3779/j.issn.1009-3419.2013.06.11
PMID:23769350
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6000570/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8458/6000570/3b98f32b100f/zgfazz-16-6-330-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8458/6000570/4001b224b6a6/zgfazz-16-6-330-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8458/6000570/3b98f32b100f/zgfazz-16-6-330-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8458/6000570/4001b224b6a6/zgfazz-16-6-330-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8458/6000570/3b98f32b100f/zgfazz-16-6-330-2.jpg

相似文献

1
[A case report of patient with advanced non-small cell lung cancer by five times EGFR-TKIs therapy].1例晚期非小细胞肺癌患者接受5次表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）治疗的病例报告
Zhongguo Fei Ai Za Zhi. 2013 Jun;16(6):330-2. doi: 10.3779/j.issn.1009-3419.2013.06.11.
2
[Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].酪氨酸激酶抑制剂的耐药机制与治疗策略
Zhongguo Fei Ai Za Zhi. 2011 Oct;14(10):806-10. doi: 10.3779/j.issn.1009-3419.2011.10.07.
3
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.阿法替尼：一种用于治疗晚期非小细胞肺癌的第二代表皮生长因子受体和ErbB酪氨酸激酶抑制剂。
Future Oncol. 2015 Sep;11(18):2525-40. doi: 10.2217/fon.15.183. Epub 2015 Aug 28.
4
Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.环孢素A通过抑制信号转导和转录激活因子3（STAT3）使人类非小细胞肺癌细胞对吉非替尼敏感。
Cancer Lett. 2016 Aug 28;379(1):124-33. doi: 10.1016/j.canlet.2016.06.002. Epub 2016 Jun 2.
5
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.非小细胞肺癌治疗的靶向疗法：聚焦于表皮生长因子受体抑制
Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23. doi: 10.1053/j.semtcvs.2008.09.005.
6
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.针对非小细胞肺癌细胞中的表皮生长因子受体：RNA 干扰与酪氨酸激酶抑制剂或西妥昔单抗联合的效果。
BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28.
7
Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib.吉非替尼或厄洛替尼治疗晚期非小细胞肺癌的目标治疗中的替代生存终点。
J Cancer Res Clin Oncol. 2012 Nov;138(11):1963-9. doi: 10.1007/s00432-012-1278-z. Epub 2012 Jul 5.
8
[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].对于曾从吉非替尼治疗中获益的晚期非小细胞肺癌患者，在表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）再治疗中如何选择：继续使用原药还是换用第二代EGFR-TKI？
Zhongguo Fei Ai Za Zhi. 2013 Jul;16(7):345-52. doi: 10.3779/j.issn.1009-3419.2013.07.03.
9
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.表皮生长因子受体激活突变的晚期非鳞状非小细胞肺癌患者一线应用吉非替尼联合或不联合培美曲塞的随机 II 期临床试验。
J Clin Oncol. 2016 Sep 20;34(27):3258-66. doi: 10.1200/JCO.2016.66.9218. Epub 2016 Aug 9.
10
[The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].[表皮生长因子受体（EGFR）状态对接受EGFR酪氨酸激酶抑制剂（EGFR-TKIs）治疗的非小细胞肺癌患者的预测价值]
Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):375-9. doi: 10.3779/j.issn.1009-3419.2010.04.20.

本文引用的文献

1
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.培美曲塞和高剂量吉非替尼在 EGFR 突变型肺腺癌脑及软脑膜转移中的疗效：吉非替尼治疗后进展。
World J Surg Oncol. 2012 Nov 7;10:235. doi: 10.1186/1477-7819-10-235.
2
[Efficacy of erlotinib after gefitinib administration in patients with non-small cell lung cancer].吉非替尼治疗后厄洛替尼对非小细胞肺癌患者的疗效
Gan To Kagaku Ryoho. 2012 Sep;39(9):1357-61.
3
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
阿法替尼对比安慰剂用于厄洛替尼、吉非替尼治疗失败或两者都失败，以及一线或二线化疗后进展、转移性非小细胞肺癌患者（LUX-Lung 1）：一项 2b/3 期随机试验。
Lancet Oncol. 2012 May;13(5):528-38. doi: 10.1016/S1470-2045(12)70087-6. Epub 2012 Mar 26.
4
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.厄洛替尼对比化疗用于治疗晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（OPTIMAL、CTONG-0802）：一项多中心、开放标签、随机、III 期研究。
Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
5
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.厄洛替尼治疗吉非替尼耐药复发的非小细胞肺癌：最优患者选择下的临床获益。
Lung Cancer. 2011 Nov;74(2):268-73. doi: 10.1016/j.lungcan.2011.03.010. Epub 2011 May 6.
6
[Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer].[晚期非小细胞肺癌初始治疗失败后表皮生长因子受体抑制剂的再治疗]
Zhongguo Fei Ai Za Zhi. 2011 Mar;14(3):261-5. doi: 10.3779/j.issn.1009-3419.2011.03.22.
7
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
8
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.吉非替尼治疗失败后的非小细胞肺癌患者接受厄洛替尼治疗的报告汇总分析。
Lung Cancer. 2010 Apr;68(1):99-104. doi: 10.1016/j.lungcan.2009.05.006. Epub 2009 Jun 21.